Pemafibrate
Share this page
Indications
Pemafibrate is indicated for:
Approved Indications:
- Treatment of hypertriglyceridemia and mixed dyslipidemia in adults as an adjunct to diet and lifestyle modification.
- Used to reduce elevated triglycerides and increase HDL cholesterol levels.
Off-Label / Clinically Accepted Uses:
- Add-on therapy for patients on statins with residual hypertriglyceridemia.
- Management of metabolic dyslipidemia, type 2 diabetes-associated dyslipidemia, and non-alcoholic fatty liver disease (NAFLD).
Dosage & Administration
- Adults: 0.1 mg twice daily or 0.2 mg once daily.
- Maximum dose: 0.4 mg once daily if needed.
- Renal impairment: Use with caution; avoid in severe impairment.
- Hepatic impairment: Contraindicated in moderate to severe hepatic dysfunction.
- Elderly: Start at the lowest effective dose; monitor function.
- Pediatric: Safety not established.
- Administration: Take orally with or after meals.
Mechanism of Action (MOA)
Pemafibrate is a Selective Peroxisome Proliferator-Activated Receptor Alpha Modulator (SPPARM-α).
It activates hepatic PPAR-α receptors, promoting fatty acid oxidation, reducing VLDL synthesis, lowering triglycerides, and raising HDL-C, thereby improving overall lipid metabolism.
Pharmacokinetics
- Absorption: Rapid after oral administration.
- Distribution: Highly protein-bound (>99%).
- Metabolism: Extensively metabolized in the liver (mainly via CYP3A4).
- Excretion: Mainly through bile/feces; minimal renal clearance.
- Half-life: ~20 hours.
Pregnancy Category & Lactation
- Pregnancy: Category C – use only if clearly needed; potential fetal risk based on animal data.
- Lactation: Unknown if excreted in breast milk; avoid during breastfeeding or discontinue nursing.
Therapeutic Class
Lipid-regulating agent / Selective PPAR-α Modulator (SPPARM-α)
Contraindications
- Severe hepatic impairment
- Active gallbladder disease
- Known hypersensitivity to Pemafibrate or other fibrates
- Nursing mothers
Warnings & Precautions
- Monitor liver enzymes (ALT, AST) periodically.
- Risk of myopathy or rhabdomyolysis, especially when used with statins.
- Discontinue if unexplained muscle pain or abnormal liver tests occur.
- Use caution in patients with renal impairment, gallstones, or hypothyroidism.
Side Effects
Common: Abdominal discomfort, constipation, elevated liver enzymes, headache.
Serious / Rare: Myopathy, rhabdomyolysis, gallstones, pancreatitis, hypersensitivity reactions.
Drug Interactions
- Statins: Increased risk of myopathy; monitor.
- Warfarin: May enhance anticoagulant effect; monitor INR.
- Cyclosporine: Contraindicated – increases Pemafibrate exposure.
- Rifampicin: Decreases Pemafibrate level; avoid co-administration.
- Bile acid sequestrants: Reduce absorption; take separately.
Recent Updates / Guidelines
- Recent studies (PROMINENT Trial) confirm Pemafibrate effectively lowers triglycerides and is safer for kidneys and liver than traditional fibrates.
- Approved and widely used in Japan for hyperlipidemia (0.2 mg daily dose).
Storage Conditions
- Store below 30 °C, in a dry place away from light and moisture.
- Keep out of reach of children.
Dr. Abu Hanif
Medical Reviewer • MBBS, FCPS